C19-A3 GNP

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameC19-A3 GNP
Drug Alias Nameproinsulin-derive peptide immunotherapy (Cardiff University)proinsulin peptide therapy (Cardiff University)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionInsulin release stimulants
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCardiff University
China Registration ClassN/A

Develop Information

Active CompaniesCardiff University
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 1
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A